Meta Pixel

News and Announcements

8VI Holdings – FY2021 Full Year Wrap Up

  • Published August 04, 2021 12:00AM UTC
  • Publisher Wholesale Investor
  • Categories Company Updates

FY2021 has undoubtedly been another eventful year in 8VI’s journey since we embarked on our digital transformation. This year, despite the COVID-19 situation, we have stayed true to our mantra of achieving ever more with ever less and that has shone through in all aspects of our business.

We intend to remain laser-focused on building a smarter future with our growth initiatives and we are confident that the strong foundation that we have put in place enables us to strengthen our FinEduTech platform further for the next decade.

 

Register Interest

About 8VI Holdings (ASX: 8VI)

8VI Holdings Limited (“8VI”) is a Singapore-based FinEduTech company operating under the brand name VI.

Established in 2008, VI is the representation of our beliefs and roots in Value Investing and empowers the average man-on-the-street to achieve sustainable wealth as part of their mission to make investments smarter, faster and easier.

VI App, a proprietary stock analysis tool developed through 8Bit Global Pte Ltd (“8Bit”), crunches traditional financial data and simplifies the complex stock analysis and decision-making process for equity investors into easy-to-use visuals under a comprehensive framework. As a licensed Financial Adviser approved by the Monetary Authority of Singapore, 8Bit provides financial advice concerning securities and units in collective investment scheme through research analyses and research reports, through VI App.

With numerous offices across the Asia Pacific region, VI College supports a community of graduates and value investors from 29 cities globally through its flagship “VI Bootcamp” and other programmes. As the region’s leading FinEduTech provider, VI College leverages the power of technology and transforms the perception and application of value investing.

Register Interest

Capital Insights
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer

In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]

Capital Insights
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts

As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.

Join over 45,000+ sophisticated investors

Join Now